Online inquiry

IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15056MR)

This product GTTS-WQ15056MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Cancers, Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15056MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15575MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ14194MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ6968MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ3225MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ11254MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ10807MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ12192MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ1368MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-874
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW